NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer
Psilocybin FCR Early-Stage Breast Cancer
NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.
The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.
Key facts
- Kind of item
- Trial registrations
- Compound
- Psilocybin
- Conditions
- Depression, Anxiety
- Jurisdiction
- United States
- Trial registration
- NCT07909408 (ClinicalTrials.gov)
- Source
- ClinicalTrials.gov: newly registered trials (clinicaltrials.gov)
- Published
- Original
- Read it at clinicaltrials.gov
How this summary was made
The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: ClinicalTrials.gov: newly registered trials · clinicaltrials.gov
Connected to
- Kind of item
- Trial registrations
- Compound
- Psilocybin
- Conditions
- DepressionAnxiety
- Jurisdiction
- United States